Skip to main content

Advertisement

SpringerLink
Log in

Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

RLIP76, a GTPase-activating protein, is a central regulator in multiple pathways that respond to redox states and control cell growth, motility, division, and apoptosis in many malignant cancer cells. In this study, human glioblastoma cell lines U87 and U251 were stably transfected with a lentivirus vector expressing a short hairpin RNA (shRNA) targeting RLIP76. shRNA knockdown of RLIP76 induced cell cycle arrest in U87 and U251 cells and inhibited their invasiveness. Quantitative Western blot analysis revealed that cells stably underexpressing RLIP76 showed lower expression of cyclin D1 and decreased expression and activity of matrix metalloproteinase 2 compared to cells stably transfected with a control vector. Furthermore, RLIP76 expression levels were correlated with IC50 values for the antitumor drug temozolomide (TMZ). Compared with TMZ alone (17.19 ± 1.78 and 22.18 ± 1.99 μg/mL in U87 and U251 cells, respectively) or combined shGFP and TMZ (18.04 ± 1.07 and 23.040 ± 1.77 μg/mL in U87 and U251 cells, respectively), combined shRNA and TMZ therapy resulted in a significant decrease in IC50 value (7.61 ± 2.99 and 6.91 ± 2.59 μg/mL in U87 and U251 cells, respectively). Combined RLIP76 knockdown and TMZ treatment inhibited cell proliferation in vitro more effectively than either treatment alone. Furthermore, RLIP76 downregulation enhanced chemosensitivity to TMZ without affecting protein expression of MDR1 and MRP1. The results indicate that inhibition of RLIP76 expression may be an effective means for overcoming RLIP76-associated chemoresistance in human malignant glioma cells and may represent a potential gene-targeting approach for glioma treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507

    Article  PubMed  CAS  Google Scholar 

  2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166–193

    Article  PubMed  Google Scholar 

  3. Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S (2007) Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol 30:717–725

    PubMed  CAS  Google Scholar 

  4. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Rao Lelsani PC, Yadav S, Awasthi S (2010) Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer 126:1327–1338

    PubMed  CAS  Google Scholar 

  5. Singhal SS, Sehrawat A, Mehta A, Sahu M, Awasthi S (2009) Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugates. Int J Oncol 34:191–199

    Article  PubMed  CAS  Google Scholar 

  6. Drake KJ, Singhal J, Yadav S, Nadkar A, Pungaliya C, Singhal SS, Awasthi S (2007) RALBP1/RLIP76 mediates multidrug resistance. Int J Oncol 30:139–144

    PubMed  CAS  Google Scholar 

  7. Awasthi S, Singhal SS, Singhal J, Yang Y, Zimniak P, Awasthi YC (2003) Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int J Oncol 22:721–732

    PubMed  CAS  Google Scholar 

  8. Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P, Awasthi YC (2003) Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int J Oncol 22:713–720

    PubMed  CAS  Google Scholar 

  9. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D (2005) RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 6:61

    Article  PubMed  Google Scholar 

  10. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, Pikula S, Bandorowicz-Pikula J, Singh SV, Zimniak P, Awasthi YC (2000) Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 39:9327–9334

    Article  PubMed  CAS  Google Scholar 

  11. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC, Awasthi S (2005) RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res 65:991–998

    PubMed  CAS  Google Scholar 

  12. Awasthi S, Singhal SS, Srivastava SK, Zimniak P, Bajpai KK, Saxena M, Sharma R, Ziller SA III, Frenkel EP, Singh SV et al (1994) Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 93:958–965

    Article  PubMed  CAS  Google Scholar 

  13. Awasthi S, Singhal SS, Pandya U, Gopal S, Zimniak P, Singh SV, Awasthi YC (1999) ATP-dependent colchicine transport by human erythrocyte glutathione conjugate transporter. Toxicol Appl Pharmacol 155:215–226

    Article  PubMed  CAS  Google Scholar 

  14. Yadav S, Zajac E, Singhal SS, Singhal J, Drake K, Awasthi YC, Awasthi S (2005) POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. Biochem Biophys Res Commun 328:1003–1009

    Article  PubMed  CAS  Google Scholar 

  15. Singhal SS, Yadav S, Vatsyayan R, Chaudhary P, Borvak J, Singhal J, Awasthi S (2009) Increased expression of cdc2 inhibits transport function of RLIP76 and promotes apoptosis. Cancer Lett 283:152–158

    Article  PubMed  CAS  Google Scholar 

  16. Hu Y, Mivechi NF (2003) HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo. J Biol Chem 278:17299–17306

    Article  PubMed  CAS  Google Scholar 

  17. Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS (2010) RLIP76: a versatile transporter and an emerging target for cancer therapy. Biochem Pharmacol 79:1699–1705

    Article  PubMed  CAS  Google Scholar 

  18. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624–1636

    Article  PubMed  CAS  Google Scholar 

  19. Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S (2009) RLIP76: a target for kidney cancer therapy. Cancer Res 69:4244–4251

    Article  PubMed  CAS  Google Scholar 

  20. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S (2007) Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res 67:4382–4389

    Article  PubMed  CAS  Google Scholar 

  21. Singhal SS, Roth C, Leake K, Singhal J, Yadav S, Awasthi S (2009) Regression of prostate cancer xenografts by RLIP76 depletion. Biochem Pharmacol 77:1074–1083

    Article  PubMed  CAS  Google Scholar 

  22. Singhal SS, Awasthi YC, Awasthi S (2006) Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 66:2354–2360

    Article  PubMed  CAS  Google Scholar 

  23. Singhal J, Yadav S, Nagaprashantha LD, Vatsyayan R, Singhal SS, Awasthi S (2011) Targeting p53-null neuroblastomas through RLIP76. Cancer Prev Res (Phila) 4:879–889

    Article  CAS  Google Scholar 

  24. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C, Chen J, Lu Y (2012) Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol 106:473–484

    Article  PubMed  CAS  Google Scholar 

  25. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC, Awasthi S (2005) Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 70:481–488

    Article  PubMed  CAS  Google Scholar 

  26. Vatsyayan R, Chaudhary P, Lelsani PC, Singhal P, Awasthi YC, Awasthi S, Singhal SS (2009) Role of RLIP76 in doxorubicin resistance in lung cancer. Int J Oncol 34:1505–1511

    PubMed  CAS  Google Scholar 

  27. Herlyn M, Malkowicz SB (1991) Regulatory pathways in tumor growth and invasion. Lab Invest 65:262–271

    PubMed  CAS  Google Scholar 

  28. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC (1999) Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 44:23–33

    Article  PubMed  CAS  Google Scholar 

  29. Nakada M, Okada Y, Yamashita J (2003) The role of matrix metalloproteinases in glioma invasion. Front Biosci 8:e261–e269

    Article  PubMed  CAS  Google Scholar 

  30. Wang M, Wang T, Liu S, Yoshida D, Teramoto A (2003) The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20:65–72

    Article  PubMed  Google Scholar 

  31. Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21:105–112

    Article  PubMed  CAS  Google Scholar 

  32. Thorns V, Walter GF, Thorns C (2003) Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 23:3937–3944

    PubMed  CAS  Google Scholar 

  33. Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211–219

    PubMed  CAS  Google Scholar 

  34. Mousseau M, Chauvin C, Nissou MF, Chaffanet M, Plantaz D, Pasquier B, Schaerer R, Benabid A (1993) A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 29A:753–759

    Article  PubMed  CAS  Google Scholar 

  35. Sugawara I, Yamada H, Nakamura H, Sumizawa T, Akiyama S, Masunaga A, Itoyama S (1995) Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. Int J Cancer 64:322–325

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Sciences Fund Project of China (NSFC Nos.30930094).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, No. 415 Fengyang Road, Shanghai, 200003, People’s Republic of China

    Qi Wang, Jun Qian, JunYu Wang, Chun Luo, Juxiang Chen, Guohan Hu & Yicheng Lu

Authors
  1. Qi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. JunYu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juxiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guohan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yicheng Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yicheng Lu.

Additional information

Qi Wang and Jun Qian contributed equally to this study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, Q., Qian, J., Wang, J. et al. Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J Neurooncol 112, 73–82 (2013). https://doi.org/10.1007/s11060-013-1045-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-013-1045-2

Keywords

Search

Navigation